Special Issue "Botulinum Toxins: New Uses in the Treatment of Diseases"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 25 April 2022.

Special Issue Editor

Dr. Siro Luvisetto
E-Mail Website
Guest Editor
Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR) of Italy, 00015 - Monterotondo Scalo, Roma, Italy
Interests: botulinum neurotoxins; neuropathic pain; peripheral nerve; motor function; functional recovery; animal model; glial cells; Schwann cells
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Both animal and clinical studies have extensively reported the therapeutic efficacy of botulinum neurotoxins (BoNTs) in many diseases characterized by excessive muscle contractions. Since the therapeutic effects of BoNTs reside in their elective action as inhibitors of cholinergic transmission, this has given extraordinary support to the clinical use of BoNTs in pathologies such as dystonia, torticollis, blepharospasm, and many others originating from hypercholinergic dysfunctions. Today, the list of human pathologies in which treatment with BoNTs produces favorable results is constantly growing. This Special Issue, entitled “Botulinum Neurotoxins: Employ in the Treatment of Diseases”, is particularly dedicated to the collection of research on new therapeutic applications of BoNTs, both as native and engineered toxins. Both review and research articles on animal models, clinical studies, case reports, or off-label indications are welcome. The ambitious goal of this Special Issue is to provide an updated framework on the development of new applications of BoNTs for their future clinical use.

Dr. Siro Luvisetto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • botulinum toxin
  • mechanism of action
  • animal models
  • human diseases
  • clinical study
  • case report
  • off-label use
  • new indications
  • engineered toxins

Published Papers

This special issue is now open for submission.
Back to TopTop